motorway

THE PROBLEM

OVER 1 MILLION ROAD DEATHS ANNUALLY WORLDWIDE

The World Health Organization reports that road accidents claim more than 1.2 million lives each year.

  • Road traffic injuries are the leading cause of death for the 15-29 year age group and the second most common cause of death for those aged 5-14 years.

  • 43% of deceased US road traffic accident victims had drugs and 37% had alcohol found in their bloodstream.

  • 33% of patients suffering from schizophrenia and schizoaffective disorders are involved in car accidents.

  • 80 diseases and 35 therapeutic drug classes significantly impair driver safety.

  • Drug interactions with sedating drugs and impaired reaction times on aging contribute to the high mortality of drivers.



ABOUT US

International Clinical Trials specialise in the application of the latest scientific technologies to find safer drugs for patients who drive motor vehicles.

These unique methodologies supersede current methods to identify minimally sedating agents.

We save lives by finding safer drugs for patients who drive automobiles and ensure maximum commercialization of low sedating compounds.

MISSION


VISION


Constantly strive to find medications that are
safer for patients who drive cars.
Continuous worldwide annual reduction in
deaths, serious injury and property damage
caused by motor vehicle accidents.


BUSINESS MODEL

International Clinical Trials business model is based on partnerships with other pharmaceutical companies that possess minimally sedating antipsychotics.

Commercial returns for low sedating antipsychotic drugs are maximised throughout their product life cycle by early clinical trial comparisons with heavily sedating agents.



BUSINESS FOUNDER

Val Schabinsky founded International Clinical Trials in January 2005 and has served as director and chairman since incorporation occurred on 24 October 2011.

Previously he worked in various roles in the pharmaceutical industry at Bristol-Myers Squibb & Merck.

He also pioneered the positions of medical product specialist at Janssen-Cilag & medical communications manager at Pfizer.

Prior to this, he was the first person in the world to research the mechanism of acute tolerance to alcohol and obtained four years academic teaching experience in the Department of Pharmacology, University of Sydney.

Val holds a Bachelor of Science and a Master of Science degree in Pharmacology from the University of Sydney.



Contact Us

Contact us to ensure that our unique research methodologies save lives by reducing motor vehicle accidents and ensure maximum commercialization of your drug.





CONTACT US

Email Us Follow on Twitter

Val Schabinsky

Founder and Chairman

37 President Road Kellyville
NSW Australia 2155

Tel: +61298361669
Mob: +61404876694
Fax: +61298361669
Web: www.internationalclinicaltrials.com